Imiquimod: a novel treatment for lentigo maligna
Imiquimod: a novel treatment for lentigo maligna
复制标题
DOI：
10.1046/j.1365-2133.2000.03787.x
复制
发表时间：
2000-10-01
影响因子：
10.3
通讯作者：
Berth-Jones, J
中科院分区：
文献类型：
--
作者：
Ahmed, I;Berth-Jones, J
恶性雀斑是恶性雀斑黑色素瘤的原位阶段，如果不治疗，可能会进展为侵袭性黑色素瘤。它最常发生在中老年患者的面部和颈部裸露部位。使用5-10 mm边缘的传统手术是推荐的治疗方法；然而，损伤可能相当大，手术切除可能涉及广泛的整形修复。我们报告一位老年患者，头皮上有一个巨大的恶性雀斑，他不愿意做手术。我们尝试了外用5%咪喹莫特乳膏(Aldara(R))，这是一种局部免疫调节剂，最近已可用于治疗外生殖器和肛周尖锐湿疣。最初在测试区域使用，然后在整个皮损上使用，总共7个月，咪喹莫特乳膏导致了完全的临床和组织学治愈。患者已随访9个月，无复发迹象。
Lentigo maligna is the in situ phase of lentigo maligna melanoma, and if left untreated it may progress to invasive melanoma. It most commonly occurs on the exposed sites of the face and neck of middle-aged or elderly patients. Conventional surgery using a 5-10 mm margin is the recommended treatment; however, lesions can be quite large and surgical removal may involve extensive plastic repair. We report an elderly patient with a large lentigo maligna on the scalp who was reluctant to have surgery. We tried topical imiquimod 5% cream (Aldara(R)), a local immunomodulator, which has recently become available for the treatment of external genital and perianal warts. Initially used over a test area and then over the whole of the lesion, for a total of 7 months, the imiquimod cream resulted in complete clinical and histological cure. The patient has been followed up for 9 months without evidence of recurrence.